Related Experiment Video
Updated: Dec 23, 2025
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study
Young Chul Youn1, Byoung Sub Lee2, Gwang Je Kim2
1Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Background:
Oligomeric amyloid-β (Aβ) is one of the major contributors to the pathomechanism of Alzheimer's disease (AD); Aβ oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aβ (MDS-OAβ) after incubation with spiked synthetic Aβ.
Objective:
We evaluated the clinical sensitivity and specificity of the MDS-OAβ values for prediction of AD.
Methods:
The MDS-OAβ values measured using inBlood™ OAβ test in heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD.
Results:
The MDS-OAβ values were 1.43±0.30 ng/ml in AD and 0.45±0.19 (p < 0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity.
Conclusion:
MDS-OAβ to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.
Insights
A new blood test measuring amyloid-beta (Aβ) oligomers shows promise for Alzheimer's disease (AD) diagnosis. The Multimer Detection System-Oligomeric Aβ (MDS-OAβ) test demonstrated high accuracy in distinguishing AD patients from those with normal cognition.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Diagnostics
Background:
- Oligomeric amyloid-beta (Aβ) plays a key role in Alzheimer's disease (AD) pathogenesis.
- Plasma Aβ oligomerization can be quantified using the Multimer Detection System-Oligomeric Aβ (MDS-OAβ) assay.
Purpose of the Study:
- To assess the clinical sensitivity and specificity of MDS-OAβ values for predicting AD.
- To evaluate MDS-OAβ as a potential blood-based biomarker for AD diagnosis.
Main Methods:
- Plasma samples from 52 AD patients and 52 cognitively normal (NC) individuals were analyzed using the inBlood™ OAβ test.
- Participants met NINCDS-ADRDA criteria, with AD patients having at least 6 months of follow-up.
Main Results:
- MDS-OAβ levels were significantly higher in AD patients (1.43±0.30 ng/ml) compared to NC subjects (0.45±0.19 ng/ml; p < 0.001).
- A cut-off value of 0.78 ng/ml yielded 100% sensitivity and 92.31% specificity for AD detection.
Conclusions:
- The MDS-OAβ assay is a valuable blood-based biomarker for the clinical diagnosis of Alzheimer's disease.
- This assay demonstrates high sensitivity and specificity, supporting its utility in AD diagnostics.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils